Nonviral siRNA delivery systems for pancreatic cancer therapy

The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)‐based therapeutics. Recent advances...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology and bioengineering 2021-10, Vol.118 (10), p.3669-3690
Main Authors: Aghamiri, Shahin, Raee, Pourya, Talaei, Sam, Mohammadi‐Yeganeh, Samira, Bayat, Shiva, Rezaee, Delsuz, Ghavidel, Afshin A., Teymouri, Alireza, Roshanzamiri, Soheil, Farhadi, Shohreh, Ghanbarian, Hossein
Format: Article
Language:English
Subjects:
Adenocarcinoma
Animals
Antineoplastic Agents - therapeutic use
Antineoplastic drugs
Antitumor agents
Cancer therapies
Carcinoma, Pancreatic Ductal - drug therapy
Chemotherapy
combination therapy
Drug delivery
drug delivery barriers
Drug Delivery Systems
High resistance
Humans
Immunostimulation
multidrug resistance
nanoparticle
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Radiation therapy
Radiation tolerance
RNA, Small Interfering - therapeutic use
siRNA
siRNA delivery systems
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)‐based therapeutics. Recent advances in drug delivery systems hold great promise for improving siRNA‐based therapeutics and developing a new class of drugs, known as nano‐siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano‐bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in the design and development of various nonviral delivery vehicles for pancreatic cancer therapy. More importantly, codelivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed. Recent advances in drug delivery systems hold great promise for improving siRNA‐based therapeutics and developing a new class of drugs, known as nano‐siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano‐bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in the design and development of various non‐viral delivery vehicles for pancreatic cancer therapy.
ISSN:0006-3592
1097-0290
DOI:10.1002/bit.27869